Terapi Antikoagulan pada Anak

Novie Amelia Chozie, Raisa Cecilia Sarita

Sari


Seiring berkembangnya pengobatan dan teknologi di rumah sakit seperti pemasangan akses vaskular, serta kondisi penyakit pada anak, maka faktor risiko kejadian trombosis pada anak juga semakin meningkat. Kejadian trombosis ini perlu penanganan berupa terapi antikoagulan yang bertujuan untuk menurunkan risiko emboli, mencegah komplikasi, dan profilaksis bagi individu yang berisiko. Penggunaan antikoagulan pada anak di praktik klinis sehari-hari sebagian besar menggunakan data ekstrapolasi dari hasil studi pada orang dewasa. Terbatasnya data yang ada saat ini dan sistem hemostasis anak yang berbeda dengan dewasa menyebabkan penggunaan antikoagulan pada anak menjadi tantangan khusus. Beberapa pilihan terapi antikoagulan masing-masing memiliki kelebihan dan kekurangannya baik dari sisi pengaturan dosis, frekuensi pemberian, pemantauan, efikasi dan efek samping. Tinjauan pustaka ini akan membahas penggunaan antikoagulan pada anak khususnya heparin (unfractionated heparin, low molecular weight heparin), warfarin, dan perkembangan studi antikoagulan oral baru, serta pada populasi khusus yaitu anak dengan keganasan, sindrom lupus eritematosus, dan infeksi virus SARS-COV-2. 


Kata Kunci


antikoagulan, anak, trombosis, heparin, warfarin

Teks Lengkap:

PDF

Referensi


Bauman M, Massicotte MP. Thromboembolic complications in children. Dalam: Arceci RJ, Hann IM, Smith OP, penyunting. Pediatric hematology. Edisi ke-3. Massachusetts: John Wiley and Sons; 2007.h.672-86.

Hepponstall M, Chan A, Monagle P. Anticoagulation therapy in neonates, children and adolescents. Blood Cells, Mol Dis 2017;67:41-7.

Newall F, Branchford B, Male C. Anticoagulant prophylaxis and therapy in children: current challenges and emerging issues. J Thromb Haemost 2018;16:196-208.

Mahajerin A, Branchford BR, Amankwah EK, dkk. Hospital-associated venous thromboembolism in pediatrics: a systematic review and meta-analysis of risk factors and risk-assessment models. Haematologica 2015;100:1045–50.

Branchford BR, Mahajerin A, Raffini L, dkk. Recommendations for standardized risk factor definitions in pediatric hospital-acquired venous thromboembolism to inform future prevention trials: communication from the SSC of the ISTH. J Thromb Haemost 2017;15:2274-8.

Law C, Raffini L. A guide to the use of anticoagulant drugs in children. Pediatr Drugs 2015;17:105-14.

Monagle P, Newall F. Anticoagulation in children. Thromb Res 2012;130:142-6.

Monagle P, Chan AKC, Goldenberg NA, dkk. Antithrombotic therapy in neonates and children: Antithrombotic therapy and prevention of thrombosis. Edisi ke-9. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e737S-e801S.

Andrew M, Marzinotto V, Brooker LA, dkk. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost 1994;71:265–9.

Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Mitchell LG. A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: a prospective cohort study. Haematologica 2007;92:244-7.

Avila ML, Shah V, Brandao LR. Systematic review on heparin-induced thrombocytopenia in children: a call to action. J Thromb Haemost 2013;11:660-9.

Streif W, Andrew M, Marzinotto V, dkk. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood 1999;94:3007-14.

Schapkaitz E, Sherman GG, Jacobson BF, dkk. Paediatric anticoagulation guidelines. South African Med J 2012;102:171-5.

Male C, Thom K, O’Brien SH. Direct oral anticoagulants: What will be their role in children? Thromb Res 2019;173:178–85.

Albisetti M. Use of direct oral anticoagulants in children and adolescents. Hamostaseologie 2020;40:64-73.

Witt DM, Nieuwlaat R, Clark NP, dkk. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018;2:3257-91.

Polania Gutierrez JJ, Rocuts KR. Perioperative anticoagulation management. Dalam: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.

Finazzi G, Brancaccio V, Schinco P, dkk. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005;3:848-53.

Crowther MA, Ginsberg JS, Julian J, dkk. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133-8.

Manco‐Johnson MJ, Nuss R. Lupus anticoagulant in children with thrombosis. Am J Hematol 1995;48:240-3.

Goldenberg NA, Abshire T, Blatchford PJ, dkk. Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings. J Thromb Haemost 2015;13:1597-605.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18:1094-9.

World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance. Geneva PP - Geneva: World Health Organization. Diakses pada 10Oktober 2021. Didapat dari: https://apps.who.int/iris/handle/10665/331446.

Thachil J, Tang N, Gando S, dkk. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18:1023-6.

Venturini E, Montagnani C, Garazzino S, dkk. Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease. Ital J Pediatr 2020;46:139.

Goldenberg NA, Sochet A, Albisetti M, dkk. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost 2020;18:3099-105.

Loi M, Branchford B, Kim J, Self C, Nuss R. COVID-19 anticoagulation recommendations in children. Pediatr Blood Cancer 2020;67:e28485.




DOI: http://dx.doi.org/10.14238/sp23.3.2021.205-14

Refbacks

  • Saat ini tidak ada refbacks.


##submission.copyrightStatement##

##submission.license.cc.by-nc-sa4.footer##

Informasi Editorial:
Badan Penerbit Ikatan Dokter Anak Indonesia
Jl. Salemba I No 5, Jakarta 10430, Indonesia
Phone/Fax: +62-21-3912577
Email: editorial [at] saripediatri.org

Lisensi Creative Commons
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.